Coffee cuts risk of HCC recurrence
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation (OLT), a study has found.
Researchers analysed the coffee drinking patterns of patients prior to and following OLT for HCC in relation to disease recurrence. They examined HepG2 cells for proliferation and metastasis potential following treatment with adenosine, in the presence or absence of adenosine receptor antagonists. Other assessments included adenosine receptor expression and known adenosine‐mediated cancer pathways inclusive of MAPK and NF‐kappa B. Median follow-up duration was 45.5 months.
The study population included 90 patients (median age, 60 years; median body mass index, 26.95 kg/m2) who underwent OLT, among whom 16 (17.8 percent) had HCC recurrence after median of 11.5 months. There were 21 patients who died (23.2 percent) after a median of 16 months. Overall survival at 1, 3 and 5 years were 90 percent, 80 percent and 72.6 percent, respectively.
On multivariable Cox analysis, coffee intake after OLT had a significant beneficial effect on recurrence‐free survival (hazard ratio [HR], 0.60; 95 percent CI, 0.37–0.97; p=0.037).
Postoperative coffee intake was also associated with a marked improvement in overall survival (HR, 0.2936; 0.12–0.71; p=0.006). Notably, those who drank ≥3 cups of coffee per day had a longer survival than those who consumed less or no coffee (mean, 11.0 vs 7.48 years; p=0.029).
Based on experimental data, the beneficial effects of postoperative coffee consumption on HCC recurrence and survival might be partly related to the antagonist activity of caffeine on adenosine‐A2AR mediated growth‐promoting effects in HCC cells, as researchers pointed out.
The present data have implications for future recommendations for coffee consumption in patients following OLT for HCC, researchers said.